Recent evidence suggests that ccf BRAF-V600E mutational analysis in plasma provides a convenient and reliable method for detecting mutational status and is a promising non-invasive biomarker for monitoring the response to therapy in children with LCH [18,19]. Here, BRAF is linked to Langerhans cell histiocytosis.